Reduction in blood pressure improves impaired nitroglycerine-induced vasodilation in patients with essential hypertension

Hypertension Research : Official Journal of the Japanese Society of Hypertension
T MaruhashiYukihito Higashi

Abstract

Nitroglycerine-induced vasodilation (NID) is usually measured as a control test for flow-mediated vasodilation (FMD). However, NID per se is also associated with atherosclerosis. The purpose of this study was to determine the relationships among NID, FMD and blood pressure, and to evaluate the effects of antihypertensive therapy on NID in patients with hypertension. We measured NID and FMD simultaneously in 94 subjects, including 35 normotensive subjects, 26 patients with stage 1 hypertension (⩾140/90 mm Hg) and 33 patients with stage 2 hypertension (⩾160/100 mm Hg), and we evaluated the effect of antihypertensive therapy for 4 weeks on vascular function in 14 patients with hypertension. NID was smaller in patients with stage 2 hypertension than in patients with stage 1 hypertension and normotensive subjects (10.5±3.9% vs. 13.8±5.0% and 16.2±5.7%; P<0.05, respectively), whereas there was no significant difference in NID between normotensive subjects and patients with stage 1 hypertension. FMD was smaller in patients with stage 2 and stage 1 hypertension than in normotensive subjects (3.1±2.7% and 4.1±1.5% vs. 6.4±2.7%; P<0.05, respectively), whereas there was no significant difference in FMD between patients with stage 1 hypert...Continue Reading

References

Jul 5, 1990·The New England Journal of Medicine·J A PanzaS E Epstein
Jul 21, 1998·Journal of the American College of Cardiology·M R AdamsD S Celermajer
Jan 14, 1999·Journal of Hypertension·B Williams
Jan 14, 1999·The New England Journal of Medicine·R Ross
Jan 12, 2001·The American Journal of Cardiology·O T RaitakariD S Celermajer
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Jan 15, 2002·Journal of the American College of Cardiology·Mary C CorrettiUNKNOWN International Brachial Artery Reactivity Task Force
Apr 30, 2003·Hypertension·Lorenzo GhiadoniAntonio Salvetti
May 16, 2003·JAMA : the Journal of the American Medical Association·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Dec 2, 2006·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Satoshi MorimotoKatsunori Sawada
Jan 14, 2009·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Teruo InoueUNKNOWN Vascular Failure Workshop Group
Feb 6, 2009·Circulation Journal : Official Journal of the Japanese Circulation Society·Yukihito HigashiYasuki Kihara
Jul 9, 2011·Arteriosclerosis, Thrombosis, and Vascular Biology·Junko SogaUNKNOWN ROCK Study Group
Jul 17, 2012·Arteriosclerosis, Thrombosis, and Vascular Biology·Yumiko IwamotoYukihito Higashi
Mar 23, 2013·Arteriosclerosis, Thrombosis, and Vascular Biology·Tatsuya MaruhashiYukihito Higashi
May 24, 2013·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Paul A DavisLorenzo A Calò
Apr 11, 2014·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hisato Takagi, Takuya Umemoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.